替罗非班
医学
改良兰金量表
优势比
随机对照试验
内科学
冲程(发动机)
脑出血
麻醉
外科
蛛网膜下腔出血
缺血
缺血性中风
心肌梗塞
经皮冠状动脉介入治疗
工程类
机械工程
作者
Aiwu Zhang,Nihong Wu,Xintong Liu,Tao Jiang
标识
DOI:10.1016/j.jocn.2022.03.008
摘要
Background The role of continuous intravenous administration of tirofiban in endovascular therapy is still unclear. This meta-analysis aims to evaluate the 90-day functional prognosis in acute ischemic stroke patients (AIS) treated by endovascular treatment and intravenous administration of tirofiban. Methods We searched PubMed, Embase, and CENTRAL databases with the subject terms “tirofiban”, “brain ischemia”, and some related free words. Inclusion criteria were: (1) cohort study or randomized control trials; (2) AIS patients who received endovascular therapy; (3) the intervention or exposure was intravenous tirofiban monotherapy or combined with intra-arterial tirofiban; (4) containing data on modified Rankin Scale at 90 days and including at least one of the following indicators: mortality, symptomatic intracranial hemorrhage (sICH), intracranial hemorrhage (ICH), and recanalization. A summary odds ratio was calculated. Results Twelve eligible studies, consisting of 3268 AIS participants, were identified. There was a significant trend of favorable outcomes (measured by mRS at three months) in the tirofiban group (ORs = 1.36; 95% CI = 1.09–1.70). In addition, compared with the non-tirofiban group, intravenous tirofiban was significantly associated with decreased risk of 90-day mortality (ORs = 0.73; 95% CI:0.59–0.89) and increased recanalization rate (ORs = 1.50; 95% CI:1.08–2.09) but no significant difference in rates of sICH (ORs = 0.93; 95% CI = 0.70–1.24) or ICH (ORs = 0.84; 95% CI = 0.62–1.15). Conclusions Intravenous tirofiban appears to be safe and effective when used following intra-arterial tirofiban or as monotherapy in AIS patients treated by endovascular therapy, which can improve the 90-day functional outcome, decrease the 90-day mortality and increase the possibility of early recanalization without increasing rates of sICH and ICH.
科研通智能强力驱动
Strongly Powered by AbleSci AI